Zacks Investment Research | Oct 30, 2019 09:01PM ET
ABIOMED, Inc. (NASDAQ:ABMD) reported second-quarter fiscal 2020 earnings per share (EPS) of $1.03, beating the Zacks Consensus Estimate of 93 cents. The figure rose 27.2% year over year.
The Zacks Rank #5 (Strong Sell) company’s revenues came in at $205 million, missing the Zacks Consensus Estimate of $206.3 million. However, the metric improved 12.8% from the prior-year quarter.
Q2 in Detail
U.S. Impella product revenues totaled $172 million, showing an increase of 9% year over year. Per management, U.S. patient usage of the Impella heart pumps rose 14% in the quarter, with 62 new sites opened in the country.
Outside the United States, Impella product revenues totaled $33 million, highlighting an increase of 40% year over year. Japan revenues were $9.6 million in the quarter, up a substantial 135%.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.